The DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index; 20 of the 36 sources its claims cite were checked for support.
RETRACTED ARTICLE: Microbiome analyses of blood and tissues suggest cancer diagnostic approach
Open accessAbstract
Systematic characterization of the cancer microbiome provides the opportunity to develop techniques that exploit non-human, microorganism-derived molecules in the diagnosis of a major human disease. Following recent demonstrations that some types of cancer show substantial microbial contributions 1-10, we re-examined whole-genome and whole-transcriptome sequencing studies in The Cancer Genome Atlas 11 (TCGA) of 33 types of cancer from treatment-naive patients (a total of 18,116 samples) for microbial reads, and found unique microbial signatures in tissue and blood within and between most major types of cancer. These TCGA blood signatures remained predictive when applied to patients with stage Ia-IIc cancer and cancers lacking any genomic alterations currently measured on two commercial-grade cell-free tumour DNA platforms, despite the use of very stringent decontamination analyses that discarded up to 92.3% of total sequence data. In addition, we could discriminate among samples from healthy, cancer-free individuals (n = 69) and those from patients with multiple types of cancer (prostate, lung, and melanoma; 100 samples in total) solely using plasma-derived, cell-free microbial nucleic acids. This potential microbiome-based oncology diagnostic tool warrants further exploration.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
9 Valid · 1 Not valid · 7 Not checked · 97 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Substantial batch effects are known in TCGA expression and human genomic data25,26 and were replicated in metagenomic data (Fig. 1c, Extended Data Figs. 1b,d).”
§ Microbiome analyses of blood and tissues suggest cancer diagnostic approach > Results > TCGA cancer microbiome and its normalization
What the sources say
- Supportedcites [25] Choi, J.-H., Hong, S.-E. & Woo, H. G. Pan-cancer analysis of systematic batch effects on somatic sequence variations. BMC Bioinformatics 18, 211 (2017). source
The citation supports the background statement that TCGA genomic data have batch effects. The Results section reports 999 batch-biased somatic variants in pan-cancer TCGA data. The sentence attributes the replication in metagenomic data to the citing paper’s own figures, not to this source. (LLM, conf=0.91)
- Supportedcites [26] Lauss, M. et al. Monitoring of technical variation in quantitative high-throughput datasets. Cancer Inform. 12, 193–201 (2013). source
The Results section, “Batch effects are found in a variety of datasets” (page unavailable), reports that TCGA batch annotations were associated with top components across the investigated RNA-seq, miRNA-seq, methylation, and gene-expression datasets. The citation supports the sentence’s background claim about known batch effects; the metagenomic replication is presented as the citing paper’s own result. (LLM, conf=0.90)
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Fusobacterium spp. is important in the development and progression of gastrointestinal tumors1,19,34,35”
§ Microbiome analyses of blood and tissues suggest cancer diagnostic approach > Results > Biological relevance of microbe profiles
What the sources say
- Partly supportedcites [1] Bullman, S. et al. Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer. Science 358, 1443–1448 (2017). sourceExperimental — accuracy not yet measured
The paper reports that Fusobacterium persists in colorectal cancer metastases and that reducing its load in a mouse xenograft decreases tumor growth. It describes a potential contribution to colorectal cancer growth and metastasis, but does not establish its importance across gastrointestinal tumors generally; its conclusion is also more tentative than the citing sentence. (LLM, conf=0.86)
- Could not verifycites [19] The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513, 202–209 (2014). sourceExperimental — accuracy not yet measured
The Main section discusses Helicobacter pylori and Epstein–Barr virus in gastric cancer, while the Discussion describes genomic subtypes. A search of our copy for “Fusobacterium” and for bacterial involvement in gastrointestinal tumour development and progression found no passage addressing the claimed role of Fusobacterium spp. (LLM, conf=0.76)
- Not checked yetcites [34] Yamamura, K. et al. Human microbiome Fusobacterium nucleatum in esophageal cancer tissue is associated with prognosis. Clin. Cancer Res. 22, 5574–5581 (2016). source
- Partly supportedcites [35] Hsieh, Y.-Y. et al. Increased abundance of Clostridium and Fusobacterium in gastric microbiota of patients with gastric cancer in Taiwan. Sci. Rep. 8, 158 (2018). sourceExperimental — accuracy not yet measured
The Results state that F. nucleatum plays a role in colorectal cancer development, and the Discussion says evidence strongly suggests it promotes colorectal cancer growth and metastasis. But the paper describes a role in gastric cancer as only possible; it does not establish that Fusobacterium species broadly are important in the development and progression of gastrointestinal tumors. (LLM, conf=0.87)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“There is mounting evidence that blood-based microbial DNA (hereafter “mbDNA”) can be clinically informative in cancer39–44, including those featuring blood-barrier or lymphatic disruptions (e.g. COAD)39”
§ Microbiome analyses of blood and tissues suggest cancer diagnostic approach > Results > Predictions using microbial DNA in blood
What the sources say
- Not checked yetcites [39] Kwong, T. N. Y. et al. Association between bacteremia from specific microbes and subsequent diagnosis of colorectal cancer. Gastroenterology 155, 383–390.e8 (2018). source
- Not checked yetcites [40] Blauwkamp, T. A. et al. Analytical and clinical validation of a microbial cell-free DNA sequencing test for infectious disease. Nat. Microbiol. 4, 663–674 (2019). source
- Partly supportedcites [41] Hong, D. K. et al. Liquid biopsy for infectious diseases: sequencing of cell-free plasma to detect pathogen DNA in patients with invasive fungal disease. Diagn. Microbiol. Infect. Dis. 92, 210–213 (2018). sourceExperimental — accuracy not yet measured
Our copy supports only the general thrust: plasma (cell-free) NGS noninvasively detected pathogen-derived DNA in blood and gave actionable, species-level information (Discussion, 'first report of a plasma NGS test that can noninvasively identify the causal pathogen in proven IFI... may allow for earlier targeting of antifungal therapy'; Results, 7/9 concordant with biopsy, plus A. lentulus vs A. fumigatus complex distinction), and several of these subjects were cancer patients (Table 1: 73-y female with multiple myeloma s/p autologous SCT, 68-y male with mixed phenotype leukemia s/p allogeneic SCT, 39-y male with stage III adenoid cystic carcinoma). However, the paper's population is immunocompromised hosts with biopsy-proven invasive fungal disease, not microbial DNA as a marker of the cancer itself, and nothing in our copy addresses the claim's qualifier about cancers 'featuring blood-barrier or lymphatic disruptions' or colorectal cancer (COAD) — the Introduction's only cancer-related statement (tumour-derived cfDNA for monitoring tumours, Snyder et al., 2011) concerns host, not microbial, DNA. The mechanism/extension the citing sentence credits to this source is therefore absent. (LLM, conf=0.72)
- Could not verifycites [42] Burnham, P. et al. Urinary cell-free DNA is a versatile analyte for monitoring infections of the urinary tract. Nat. Commun. 9, 2412 (2018). sourceExperimental — accuracy not yet measured
Our copy of Burnham et al. (2018) is a urinary cfDNA study in 82 kidney transplant recipients with bacterial UTI or BKV nephropathy; the Introduction (p. 1) only lists cfDNA applications broadly ('with applications in pregnancy, cancer, and solid-organ transplantation') for host cfDNA, and the only cancer-related statement in Results > Host response to infection concerns elevated plasma mitochondrial (host) DNA in trauma, sepsis and cancer. No passage addresses blood-based microbial (bacterial/viral) DNA as clinically informative in cancer, nor blood-barrier or lymphatic disruption, nor colorectal cancer as a cohort; the sole colorectal-cancer mention is reference 23 (Su et al., urinary DNA 'may be useful in the detection of colorectal cancer'), a citation entry about human urinary cfDNA, not this paper's finding. Searched: 'blood-based microbial DNA clinically informative in cancer', 'plasma cfDNA tumor cancer detection colorectal', 'bacterial DNA in blood plasma sepsis cancer patients clinical utility'. (LLM, conf=0.70)
- Partly supportedcites [43] De Vlaminck, I. et al. Temporal response of the human virome to immunosuppression and antiviral therapy. Cell 155, 1178–1187 (2013). sourceExperimental — accuracy not yet measured
Our copy supports only the modality half of the claim: it shows that sequencing cell-free plasma DNA for microbial/viral sequences is clinically informative, but exclusively in solid organ transplant recipients — the Introduction states 'measurement of the anellovirus burden enables stratification of rejecting and non-rejecting recipients' and the Discussion anticipates 'hypothesis-free diagnosis of infections' in transplantation. No passage addresses cancer, tumour-bearing patients, blood-barrier or lymphatic disruption, or colorectal adenocarcinoma (searches for 'cancer/tumor/colorectal' returned only the Discussion remark that anelloviruses are 'currently under investigation as potential cofactors in carcinogenesis (zur Hausen and de Villiers, 2009)' and the known increased cancer incidence in transplant recipients — neither is a claim about mbDNA as a clinical readout in cancer). The cancer-specific extension attributed to this source is therefore not supported by it. (LLM, conf=0.65)
- Partly supportedcites [44] Huang, Y.-F. et al. Analysis of microbial sequences in plasma cell-free DNA for early-onset breast cancer patients and healthy females. BMC Med. Genomics 11 (Suppl. 1), 16 (2018). sourceExperimental — accuracy not yet measured
Our copy supports the general part: the Abstract Background states 'Microbial sequences in plasma cfDNA may provide important information to improve prognosis and treatment' and the Abstract Conclusions say the profiles 'may have some prognostic value in cancer patients' (breast cancer, EOBC patients vs healthy females). However, the sentence attaches this citation specifically to cancers 'featuring blood-barrier or lymphatic disruptions (e.g. COAD)', and this paper studies only early-onset breast cancer and healthy females — it makes no mention of colorectal cancer, blood-barrier or lymphatic disruption; on the contrary, its Conclusions list patients 'with different types of cancer and/or different cancer stages' as a future intention. The unsupported part is the blood-barrier/lymphatic-disruption (COAD) attribution. (LLM, conf=0.78)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“We further used gene-lists from the Guardant360® and FoundationOne® Liquid assays45,46 to filter out TCGA patients with ≥1 targeted modification (~70%; Extended Data Figs. 8c–e) and found high discriminatory performances using the same ML approach for most remaining cancer types”
§ Microbiome analyses of blood and tissues suggest cancer diagnostic approach > Results > Predictions using microbial DNA in blood
What the sources say
- Could not verifycites [45] Bettegowda, C. et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci. Transl. Med. 6, 224ra24 (2014). sourceExperimental — accuracy not yet measured
Our full-text copy of Bettegowda et al. (2014) contains no mention of the Guardant360 or FoundationOne Liquid assays, no TCGA cohort, no ~70% filtering step, and no machine-learning/methylated-DNA (mbDNA) discrimination analysis; the paper's own analyses are digital PCR/BEAMing and low-coverage whole-genome detection of point mutations and rearrangements in 640 patients (Abstract; Results, 'Patients with metastatic cancers'), plus a custom multiplexed hotspot panel for KRAS/NRAS/BRAF/EGFR/PIK3CA (Results, 'Monitoring patients for resistance-conferring mutations') and a blinded KRAS liquid-biopsy panel with 87.2% sensitivity/99.2% specificity (Results, 'The sensitivity and specificity of liquid biopsy'). Searches for 'Guardant360', 'FoundationOne', 'commercial plasma assay gene list', 'TCGA', 'machine learning classifier methylation', and 'discrimination/AUC' returned only unrelated references and the above ctDNA passages. Nothing in our copy contradicts the claim either, so the attributed content can be neither confirmed nor refuted from this source. (LLM, conf=0.78)
- Partly supportedcites [46] Clark, T. A. et al. Analytical validation of a hybrid capture-based next-generation sequencing clinical assay for genomic profiling of cell-free circulating tumor DNA. J. Mol. Diagn. 20, 686–702 (2018). sourceExperimental — accuracy not yet measured
Clark et al. (2018) is the validation publication of Foundation Medicine's blood-based hybrid capture cfDNA/ctDNA panel: the Materials and Methods 'Panel Design, Hybrid Capture, and Sequencing' section enumerates the targeted gene content (all exons of 27 genes, selected exons of 33 additional genes, selected introns of 6 rearrangement genes, TERT promoter; Supplemental Table S1) and the Discussion calls it 'a panel of 62 cancer-related genes' — so the assay gene-list part of the attribution is in our copy. However, our copy names that assay FoundationACT throughout and never uses the product name 'FoundationOne Liquid'; the only 'FoundationOne' it describes is the separate tissue assay (Materials and Methods, 'Hybrid Capture–Based NGS with FoundationOne'). The ~70% TCGA filtering and the retained machine-learning discrimination are the citing authors' own analysis and appear nowhere in this source, which reports analytical validation on 2666 reference alterations and 860–884 clinical cases instead. (LLM, conf=0.70)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“we repeated all bioinformatic, normalization, and ML steps using bacterial assignments from SHOGUN31 and its separate database48, which showed highly concordant performances”
§ Microbiome analyses of blood and tissues suggest cancer diagnostic approach > Results > Validating microbial signatures in blood
What the sources say
- Supportedcites [31] Hillmann, B. et al. Evaluating the information content of shallow shotgun metagenomics. mSystems 3, e00069-18 (2018). source
This is an identification/method citation: the citing sentence attaches ref 31 to SHOGUN as the tool that produced the bacterial (species-level) assignments, and our copy of Hillmann et al. 2018 is exactly that method paper — Materials and Methods > 'Shotgun species profiling' describes mapping trimmed query reads against RefSeq v82 representative/reference genomes with a confidence-adjusted LCA retaining species-level assignments, with source code at github.com/knights-lab/SHOGUN, and 'Human microbiome project data' describes running 'the SHOGUN pipeline to quantify species and gene profiles'. The 'separate database' element is carried by the adjacent reference 48, not by this citation, though our copy is consistent with it (RefSeq v82 genomes and KEGG Orthology annotations for RefSeq-derived genes). The 'highly concordant performances' clause is the citing authors' own repeat-analysis result and is not attributed to this source, so nothing here overstates the cited paper. (LLM, conf=0.85)
- Could not verifycites [48] Huang S. et al. Human skin, oral, and gut microbiomes predict chronological age. mSystems 5, e00630-19 (2020). sourceExperimental — accuracy not yet measured
Our copy of Huang et al. (2020, mSystems) describes only a Deblur-ASV/QIIME 2 pipeline with random-forest regression on ASV relative abundances (OBSERVATION, methods paragraphs), and no passage mentions SHOGUN, a separate SHOGUN database, or a repeat of the bioinformatic/normalization/ML steps with an alternative taxonomic profiler. Searched: 'SHOGUN bacterial assignments ... concordant performance', 'alternative taxonomic profiler robustness sensitivity analysis', 'concordant performance', and 'supplemental material additional analysis normalization OTU table' — no exact or semantic hit for the attributed re-analysis. Absence in our copy is not contradiction, and our copy is not truncated, but the specific SHOGUN replication claim is simply not addressed here. (LLM, conf=0.62)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
46 more claims · 4 with their cited sources checked
Create a free account to see all 114 claims and to verify the 16 references still open.
- It may state two separate claims as one. 43
- Probably not a substantial claim. 36
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“analyses of TCGA datasets identified unique microbial signatures in blood that could distinguish between healthy and cancer patients”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Poore et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A growing body of evidence has demonstrated the presence of intratumoral microbes, with studies using either metagenomics or culturomics suggesting the presence of intracellular,14,38,102,103 cancer type-specific,14,104–106 spatially heterogeneous,14,103,107 metabolically active,14,38,49,108,109 pro-metastatic,102,103,110,111 and immunoreactive38,60,112–115 communities of tumor-resident bacteria,”
From Melanoma and microbiota: Current understanding and future directions (2024) · cites this paper as [104]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Machine learning revealed intratumor, cancer-specific microbial signatures.”
From The microbiome and human cancer (2021) · cites this paper as [13]
The cited source says what the claim attributes to it.
In the citing paper
“They validated this blood-based diagnostic approach by comparing plasma-derived cell-free microbial DNA from 100 patients with lung, prostate, or melanoma cancers to those from 69 HIV-negative, healthy patients while implementing necessary experimental contamination controls.”
From The microbiome and human cancer (2021) · cites this paper as [13]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“whether translocated bacteria impact on tumor immunity or ICI from directly within the tumor remained unknown”
From Dietary tryptophan metabolite released by intratumoral Lactobacillus reuteri facilitates immune checkpoint inhibitor treatment (2023) · cites this paper as [27]
Experimental — accuracy not yet measured
10 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Microbiome analyses of blood and tissues suggest cancer diagnostic approach > Results > Predicting among and within cancer types
“a reduced, phylogenetically-based, bacteria-only database”
§ Microbiome analyses of blood and tissues suggest cancer diagnostic approach > Methods > SHOGUN TCGA bioinformatic processing
“a separate phylogeny-centric database called ‘Web of Life’ (WoL; developed by Q.Z. & R.K.; n=10,575 bacterial and archaeal genomes; https://biocore.github.io/wol/data/genomes)48”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Microbiome analyses of blood and tissues suggest cancer diagnostic approach > Methods > Kraken TCGA microbial-detection pipeline
“we took four cancer types (COAD, CESC, OV, LUAD) and aligned the reads Kraken classified as “microbial” to the 59,974 microbial genomes using BWA50”
§ Microbiome analyses of blood and tissues suggest cancer diagnostic approach > Methods > Kraken TCGA microbial-detection pipeline
“The four cancer types that were directly aligned included CESC as a putative positive viral control (i.e. HPV), STAD as a putative positive bacterial control (i.e. H. pylori), and two others (LUAD, OV)”
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Trimmomatic: a flexible trimmer for Illumina sequence data
Bolger, A. M., Lohse, M., & Usadel, B. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu170 · Cited by 65,548
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
Fast gapped-read alignment with Bowtie 2
Langmead, B., & Salzberg, S. L. (2012) · Nature Methods · doi:10.1038/nmeth.1923 · Cited by 56,400
Robinson, M. D., McCarthy, D. J., & Smyth, G. K. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp616 · Cited by 41,364
limma powers differential expression analyses for RNA-sequencing and microarray studies
Ritchie, M. E., Phipson, B., Wu, D., Hu, Y., Law, C. W., Shi, W., & Smyth, G. K. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv007 · Cited by 40,458
Greedy function approximation: A gradient boosting machine
Friedman, J. H. (2001) · The Annals of Statistics · doi:10.1214/aos/1013203451 · Cited by 30,731
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2
Bolyen, E., Rideout, J. R., Dillon, M. R., Bokulich, N. A., Abnet, C. C., Al-Ghalith, G. A., Alexander, H., Alm, E. J., Arumugam, M., Asnicar, F., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0209-9 · Cited by 23,742
Self-citationA global reference for human genetic variation
The 1000 Genomes Project Consortium, authors, C., Auton, A., Abecasis, G. R., Steering committee, Altshuler, D. M., Durbin, R. M., Abecasis, G. R., Bentley, D. R., Chakravarti, A., et al. (2015) · Nature · doi:10.1038/nature15393 · Cited by 18,247
Cited by
The human tumor microbiome is composed of tumor type–specific intracellular bacteria
Nejman, D., Livyatan, I., Fuks, G., Gavert, N., Zwang, Y., Geller, L. T., Rotter-Maskowitz, A., Weiser, R., Mallel, G., Gigi, E., et al. (2020) · Science · doi:10.1126/science.aay9189 · Cited by 2,464
Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
Morad, G., Helmink, B. A., Sharma, P., & Wargo, J. A. (2021) · Cell · doi:10.1016/j.cell.2021.09.020 · Cited by 1,648
The microbiome and human cancer
Sepich-Poore, G. D., Zitvogel, L., Straussman, R., Hasty, J., Wargo, J. A., & Knight, R. (2021) · Science · doi:10.1126/science.abc4552 · Cited by 1,332
Self-citationSawicki, T., Ruszkowska, M., Danielewicz, A., Niedźwiedzka, E., Arłukowicz, T., & Przybyłowicz, K. E. (2021) · Cancers · doi:10.3390/cancers13092025 · Cited by 921
Effect of the intratumoral microbiota on spatial and cellular heterogeneity in cancer
Galeano Niño, J. L., Wu, H., LaCourse, K. D., Kempchinsky, A. G., Baryiames, A., Barber, B., Futran, N., Houlton, J., Sather, C., Sicinska, E., et al. (2022) · Nature · doi:10.1038/s41586-022-05435-0 · Cited by 887
Metadata
- Authors
- Poore, G. D., Kopylova, E., Zhu, Q., Carpenter, C., Fraraccio, S., Wandro, S., Kosciolek, T., Janssen, S., Metcalf, J., Song, S. J., Kanbar, J., Miller-Montgomery, S., Heaton, R., Mckay, R., Patel, S. P., Swafford, A. D., & Knight, R.
- Affiliations
- University of California San Diego (US)
- Justus-Liebig-Universität Gießen (DE)
- Colorado State University (US)
- Corresponding author
- Knight, Rob
- ORCID
- Venue
- Nature
- Published
- 2020-03-11
- Volume
- 579
- Issue
- 7800
- Pages
- 567-574
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC7500457
- OpenAlex
- W3010810358
- Cited by
- 989
- References
- 81
- Citations by year
- 2026: 50 · 2025: 108 · 2024: 186 · 2023: 248 · 2022: 210 · 2021: 134 · 2020: 53
- FWCI
- 55.68
- Type
- journal article
- Language
- en
- Status
- Retracted
- Update notices
- retraction (2024-06-26)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institute on Alcohol Abuse and Alcoholism (R00AA020235)
- National Institute of Mental Health (P30MH062512)
- National Institute on Drug Abuse (P50DA026306, P01DA012065, R01DA026334)
- National Cancer Institute (HHSN261201400008C, F30CA243480, HHSN261201500003I, P30CA023100, HHSN261201500003C)
- National Institute of General Medical Sciences (T32GM007198)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Phylogenetic Studies
- Keywords
- tumor microbiome, microbial signatures, cancer diagnosis, plasma, tissues, TCGA, microbial decontamination, machine learning classification, prostate cancer, lung cancer, melanoma, retracted article
- MeSH terms
- Liquid Biopsy, DNA, Bacterial, DNA, Viral, Female, Humans, Lung Neoplasms, Male, Melanoma, Neoplasms, Plasma, Prostatic Neoplasms, Reproducibility of Results, Cohort Studies, Case-Control Studies, Microbiota, Datasets as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: RETRACTED ARTICLE: Microbiome analyses of blood and tissues suggest cancer diagnostic approach. https://app.cochat.ai/papers/10.1038/s41586-020-2095-1
- The paper
- Poore, G. D., Kopylova, E., Zhu, Q., Carpenter, C., Fraraccio, S., Wandro, S., Kosciolek, T., Janssen, S., Metcalf, J., Song, S. J., Kanbar, J., Miller-Montgomery, S., Heaton, R., Mckay, R., Patel, S. P., Swafford, A. D., & Knight, R. (2020). RETRACTED ARTICLE: Microbiome analyses of blood and tissues suggest cancer diagnostic approach. Nature. https://doi.org/10.1038/s41586-020-2095-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.